Expression profile of host restriction factors in HIV-1 elite controllers

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Abdel Mohsen, Mohamed ^a,e   Raposo, Rui André S ^b   Deng, Xutao ^c   Li, Manqing ^d   Liegler, Teri ^a   Sinclair, Elizabeth ^a   Salama, Mohamed S ^e   Ghanem, Hussam E A ^e   Hoh, Rebecca ^a   Wong, Joseph K ^a,f   David, Michael ^d   Nixon, Douglas F ^b   Deeks, Steven G ^a   Pillai, Satish K ^a,c,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^d SECTION OF MOLECULAR BIOLOGY   (United States)

^e Ain Shams University   (Egypt)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

APOBEC3; BST2 tetherin; Elite controllers; Intrinsic immunity; p21; Retroviral restriction factors; schlafen 11; T cell activation; TRIM

Indexed keywords

APOBEC3C PROTEIN; APOBEC3D PROTEIN; CTR9 PROTEIN; HOST RESTRICTION FACTOR; INTERFERON STIMULATED GENE 15; MESSENGER RNA; MICROORGANISM PROTEIN; SCHLAFEN 11; TRIM26 PROTEIN; TRIM32 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; VIRUS LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; NUCLEAR PROTEINS;

EID: 84885437063     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-106     Document Type: Article

References (55)

1. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010, 376:49. 10.1016/S0140-6736(10)60676-9, 20609987.
2. Zaunders J, van Bockel D. Innate and adaptive immunity in long-term non-progression in HIV disease. Front Immunol 2013, 4:95. 3633949, 23630526.
3. Saag M, Deeks SG. How do HIV elite controllers do what they do?. Clin Infect Dis 2010, 51:239. 10.1086/653678, 20550453.
4. Cruz NV, Amorim R, Oliveira FE, Speranza FA, Costa LJ. Mutations in the nef and vif genes associated with progression to AIDS in elite controller and slow-progressor patients. J Med Virol 2013, 85:563. 10.1002/jmv.23512, 23417613.
5. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007, 81:2508. 10.1128/JVI.02165-06, 1865922, 17151109.
6. Dyer WB, Zaunders JJ, Yuan FF, Wang B, Learmont JC, Geczy AF, Saksena NK, McPhee DA, Gorry PR, Sullivan JS. Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology 2008, 5:112. 10.1186/1742-4690-5-112, 2633348, 19077215.
7. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781. 10.1182/blood-2005-12-4818, 1895811, 16467198.
8. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008, 197:126. 10.1086/524143, 3466592, 18171295.
9. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008, 82:5398. 10.1128/JVI.02176-07, 2395228, 18353945.
10. Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M, Ehler L, Metcalf J, Liu S, Hallahan CW, Connors M. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J Virol 2003, 77:6889. 10.1128/JVI.77.12.6889-6898.2003, 156173, 12768008.
11. Vigneault F, Woods M, Buzon MJ, Li C, Pereyra F, Crosby SD, Rychert J, Church G, Martinez-Picado J, Rosenberg ES, Telenti A, Yu XG, Lichterfeld M. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers. J Virol 2011, 85:3015. 10.1128/JVI.01846-10, 3067917, 21177805.
12. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Gunthard HF, Goldstein DB, Telenti A. H. I. V. C. S. Swiss, H. I. V. A. V. I. Center for, Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog 2010, 6:e1000781. 10.1371/journal.ppat.1000781, 2829051, 20195503.
13. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011, 121:1549. 10.1172/JCI44539, 3069774, 21403397.
14. Saez-Cirion A, Hamimi C, Bergamaschi A, David A, Versmisse P, Melard A, Boufassa F, Barre-Sinoussi F, Lambotte O, Rouzioux C, Pancino G. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood 2011, 118:955. 10.1182/blood-2010-12-327106, 3148172, 21642597.
15. Rabi SA, O'Connell KA, Nikolaeva D, Bailey JR, Jilek BL, Shen L, Page KR, Siliciano RF, Blankson JN. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol 2011, 85:979. 10.1128/JVI.01721-10, 3020020, 21068257.
16. O'Connell KA, Rabi SA, Siliciano RF, Blankson JN. CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors. Proc Natl Acad Sci USA 2011, 108:E689. 10.1073/pnas.1108866108, 3174588, 21873218.
17. Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, Baker BM, Lian J, Miura T, Martinez-Picado J, Addo MM, Walker BD. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis 2010, 51:233. 10.1086/653677, 3749734, 20550452.
18. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848. 10.1038/nature02343, 14985764.
19. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646. 10.1038/nature00939, 12167863.
20. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3:245. 10.1016/j.chom.2008.03.001, 2474773, 18342597.
21. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425. 10.1038/nature06553, 18200009.
22. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Gunthard HF, Wong JK. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci USA 2012, 109:3035. 10.1073/pnas.1111573109, 3286922, 22315404.
23. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 2008, 82:3125. 10.1128/JVI.01533-07, 2259015, 18077705.
24. Tong-Starksen SE, Luciw PA, Peterlin BM. Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci USA 1987, 84:6845. 10.1073/pnas.84.19.6845, 299181, 3498942.
25. Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC. Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science 1987, 238:1575. 10.1126/science.2825351, 2825351.
26. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 2004, 78:6073. 10.1128/JVI.78.11.6073-6076.2004, 415831, 15141007.
27. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004, 11:435. 10.1038/nsmb758, 15098018.
28. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004, 14:1392. 10.1016/j.cub.2004.06.057, 15296758.
29. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 2004, 279:53379. 10.1074/jbc.M408802200, 15466872.
30. Bourara K, Liegler TJ, Grant RM. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog 2007, 3:1477. 2042017, 17967058.
31. Abudu A, Wang X, Dang Y, Zhou T, Xiang SH, Zheng YH. Identification of molecular determinants from Moloney leukemia virus 10 homolog (MOV10) protein for virion packaging and anti-HIV-1 activity. J Biol Chem 2012, 287:1220. 10.1074/jbc.M111.309831, 3256871, 22105071.
32. Dang Y, Siew LM, Wang X, Han Y, Lampen R, Zheng YH. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem 2008, 283:11606. 10.1074/jbc.M707586200, 2430661,2430661, 18299330.
33. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, Bouaziz S, Muriaux D, Darlix JL, Cimarelli A. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog 2011, 7:e1002221. 10.1371/journal.ppat.1002221, 3178557, 21966267.
34. Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F, Mothes W, Hazan U, Transy C, Pancino G, Nisole S. Human TRIM gene expression in response to interferons. PLoS One 2009, 4:e4894. 10.1371/journal.pone.0004894, 2654144, 19290053.
35. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 2008, 4:e16. 10.1371/journal.ppat.0040016, 2222954, 18248090.
36. Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 2008, 4:e1000007. 10.1371/journal.ppat.1000007, 2279259, 18389079.
37. Zhang J, Attar E, Cohen K, Crumpacker C, Scadden D. Silencing p21(Waf1/Cip1/Sdi1) expression increases gene transduction efficiency in primitive human hematopoietic cells. Gene Ther 2005, 12:1444. 10.1038/sj.gt.3302544, 15877047.
38. Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007, 117:473. 10.1172/JCI28971, 1783820, 17273559.
39. Liu L, Oliveira NM, Cheney KM, Pade C, Dreja H, Bergin AM, Borgdorff V, Beach DH, Bishop CL, Dittmar MT, McKnight A. A whole genome screen for HIV restriction factors. Retrovirology 2011, 8:94. 10.1186/1742-4690-8-94, 3228845, 22082156.
40. Muto NF, Martinand-Mari C, Adelson ME, Suhadolnik RJ. Inhibition of replication of reactivated human immunodeficiency virus type 1 (HIV-1) in latently infected U1 cells transduced with an HIV-1 long terminal repeat-driven PKR cDNA construct. J Virol 1999, 73:9021. 112934, 10516008.
41. Woods MW, Kelly JN, Hattlmann CJ, Tong JG, Xu LS, Coleman MD, Quest GR, Smiley JR, Barr SD. Human HERC5 restricts an early stage of HIV-1 assembly by a mechanism correlating with the ISGylation of Gag. Retrovirology 2011, 8:95. 10.1186/1742-4690-8-95, 3228677, 22093708.
42. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. J Virol 2011, 85:2126. 10.1128/JVI.01531-10, 3067758, 21177806.
43. Pincetic A, Kuang Z, Seo EJ, Leis J. The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. J Virol 2010, 84:4725. 10.1128/JVI.02478-09, 2863725, 20164219.
44. Furtak V, Mulky A, Rawlings SA, Kozhaya L, Lee K, Kewalramani VN, Unutmaz D. Perturbation of the P-body component Mov10 inhibits HIV-1 infectivity. PLoS One 2010, 5:e9081. 10.1371/journal.pone.0009081, 2816699, 20140200.
45. Malathi K, Dong B, Gale M, Silverman RH. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 2007, 448:816. 10.1038/nature06042, 3638316, 17653195.
46. Nasr N, Maddocks S, Turville SG, Harman AN, Woolger N, Helbig KJ, Wilkinson J, Bye CR, Wright TK, Rambukwelle D, Donaghy H, Beard MR, Cunningham AL. HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood 2012, 120:778. 10.1182/blood-2012-01-407395, 22677126.
47. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474:658. 10.1038/nature10195, 3179858, 21720370.
48. Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, Jones TE, Landry S, Pan T, Weitzman MD, David M. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature 2012, 491:125. 10.1038/nature11433, 3705913, 23000900.
49. Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, Colle JH, Urrutia A, Scott-Algara D, Boufassa F, Delfraissy JF, Theze J, Venet A, Chakrabarti LA. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007, 81:13904. 10.1128/JVI.01401-07, 2168869, 17928341.
50. van Grevenynghe J, Procopio FA, He Z, Chomont N, Riou C, Zhang Y, Gimmig S, Boucher G, Wilkinson P, Shi Y, Yassine-Diab B, Said EA, Trautmann L, El Far M, Balderas RS, Boulassel MR, Routy JP, Haddad EK, Sekaly RP. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med 2008, 14:266. 10.1038/nm1728, 18311149.
51. Raposo RA, Abdel-Mohsen M, Bilska M, Montefiori DC, Nixon DF, Pillai SK. Effects of Cellular Activation on Anti-HIV-1 Restriction Factor Expression Profile in Primary Cells. J Virol 2013, 87(21):11924-11929. doi:10.1128/JVI.02128-13. Epub 2013 Aug 21, 10.1128/JVI.02128-13, 23966394.
52. Raposo RA, Abdel-Mohsen M, Holditch SJ, Kuebler PJ, Cheng RG, Eriksson EM, Liao W, Pillai SK, Nixon DF. Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. J Leukoc Biol 2013, Epub ahead of print.
53. Oxenius A, Price DA, Gunthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, Garcia F, Hirschel B, McLean A, Phillips RE. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002, 99:13747. 10.1073/pnas.202372199, 129766, 12370434.
54. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Delfraissy JF. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23:897. 10.1097/QAD.0b013e328329f97d, 3652655, 19414990.
55. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A. Speleman, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. RESEARCH0034.